Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047981 · ClinicalTrials.gov registry record · Phase 4
Mortality Reduction After Oral Azithromycin: Mortality Study
A Phase 4 study of Childhood Mortality, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 190,238
- Enrollment target
- 6
- Study locations
NCT02047981: Completed Phase 4 study of Childhood Mortality, sponsored by University of California, San Francisco.
NCT02047981 is a Phase 4 study of Childhood Mortality that has completed, run by University of California, San Francisco. The registered enrollment target is 190,238 participants, above the 498-participant average among 9,235 other Phase 4 trials with a reported enrollment target (38100% higher). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02047981, a Phase 4 study of Childhood Mortality, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 190,238 participants
- Enrollment target
- 6
- Study locations
Study Summary
Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.
Primary Outcome
This is a single multi-site trial, with each country as a secondary analysis. Also, an interim analysis of efficacy and futility will be conducted according to a pre-specified plan in the Statistical Analysis Plan.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azithromycin
Study Locations (6)
Other
- College of Medicine at the University of Malawi, Blantyre - Blantyre
- The Carter Center, Niger - Niamey
- Kongwa Trachoma Project - Kongwa
- London School of Hygiene & Tropical Medicine - London
California
- UCSF Proctor Foundation - San Francisco
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190,238 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-09 |
| Phase | Phase 4 |
What the finished NCT02047981 record still lists
NCT02047981 is an interventional study that assigns participants to a tested intervention. Its 190,238 participants enrollment target places it among the larger protocols in the corpus, above the 498-participant average among 9,235 other Phase 4 trials with a reported enrollment target (38100% higher).
The record links to 1 condition, with Childhood Mortality appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02047981 lists 6 locations in 3 states (Other, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT02047981 about?
NCT02047981 is a clinical study titled "Mortality Reduction After Oral Azithromycin: Mortality Study". Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo...
What is the current status of trial NCT02047981?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 190,238 participants. The study started on 2014-12. Estimated completion is 2018-09.
What conditions does trial NCT02047981 study?
This clinical trial studies the following conditions: Childhood Mortality.
What interventions are being tested in trial NCT02047981?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT02047981?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02047981 being conducted?
This trial has 6 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02047981's enrollment target sits among peer trials
190,238 4th of 2000 higher than 1,997 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia